Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Operating Expenses (2016 - 2025)

Anaptysbio (ANAB) has disclosed Operating Expenses for 10 consecutive years, with $41.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 21.66% year-over-year to $41.3 million, compared with a TTM value of $186.7 million through Dec 2025, down 9.47%, and an annual FY2025 reading of $186.7 million, down 9.47% over the prior year.
  • Operating Expenses was $41.3 million for Q4 2025 at Anaptysbio, down from $41.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $55.3 million in Q1 2025 and bottomed at $27.7 million in Q3 2021.
  • Average Operating Expenses over 5 years is $41.0 million, with a median of $41.5 million recorded in 2025.
  • The sharpest move saw Operating Expenses skyrocketed 56.01% in 2023, then fell 21.66% in 2025.
  • Year by year, Operating Expenses stood at $32.2 million in 2021, then rose by 1.91% to $32.8 million in 2022, then surged by 56.01% to $51.1 million in 2023, then increased by 3.21% to $52.8 million in 2024, then decreased by 21.66% to $41.3 million in 2025.
  • Business Quant data shows Operating Expenses for ANAB at $41.3 million in Q4 2025, $41.6 million in Q3 2025, and $48.4 million in Q2 2025.